An Ultrathin-Strut, Biodegradable-Polymer, Sirolimus-Eluting Stent: Long-Term Outcomes

At 5 years, this stent had similar safety and efficacy to a durable-polymer, everolimus-eluting stent.

Current trends in drug-eluting stent design have favored thinner struts to improve deliverability and reduce stent thrombosis, as well as biodegradable polymers to promote healing and mitigate late adverse events. In a manufacturer-funded, randomized study (NCT01443104), 2119 patients received a biodegradable-polymer, ultrathin-strut (60–80 µm) sirolimus-eluting stent (SES) or a durable-polymer, thin-strut (81 µm) everolimus-eluting stent (EES).

At 5 years, follow-up was available in 95% of patients. Target-lesion failure occurred in a similar percentage of patients in both groups (SES, 20%; EES, 19%). The rate of definite stent thrombosis (1.6%) was the same in both groups. All-cause mortality was significantly higher with SES (14%) than wi…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)